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Ayurveda has given prime importance to Mutravaha srotas (urinary system) and Srotogata vikaras (urinary disorders). 
Acharyas of Ayurveda has described many aspects of Mutravaha srotasa (urinary system) and described diseases pertaining 
to it. Mulaka (Raphanus sativus Linn.) belongs to family Brasicassea, traditionally being used in kidney disorders. Mulaka 
was firstly introduced in Charak Samhita and used for urinary system related problems. Hence, present study was planned 
with an aim to prove the traditional claims on Ayurvedic formulations of Mulaka i.e., powder of Mulaka panchanga and 
Mulaka kshara. Mulaka panchanga (450 and 900 mg/kg) and Mulaka kshara (90 and 180 mg/kg) were evaluated for 
nephroprotective activity by using cisplatin (5 mg/kg, ip) –induced nephrotoxicity in albino rats. Cisplatin increases the 
levels of blood urea, uric acid and serum creatinine which suggest the kidney damage in rats. Cisplatin–induced the 
hepatotoxicity was confirmed by increase in the level of serum transaminases, alkaline phosphatase and bilirubin with 
increase in the level of serum cholesterol and triglyceride. Both formulations reversed the serum biochemical parameters 
and urine creatinine levels with an increase in the urine volume. Further, powder of Mulaka panchanga and Mulaka kshara, 
attenuated the level of free radicals with concomitantly increase in antioxidant parameters in kidney tissue homogenate and 
thus, protect the kidney cytoarchitecture in histopathological study. The result of present study indicates that Mulaka 
panchanga and Mulaka kshara both having nephroprotective and antioxidant properties in dose dependent manner in 
cisplatin–induced nephrotoxicity in rats. 
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Renal disorders have always remained a major area  
of concern for health. These days, use of analgesic, 
Nonsteroidal anti-inflammatory drugs (NSAID), 
antidepressant, antibiotic and chemotherapy agents 
carry adverse drug effects on kidney. Kidneys are 
frequently exposed to these drugs and/or toxic 
metabolites and are therefore, a common site for drug 
toxicity results in serious clinical syndromes1. Charaka 
Samhita contains several sections on urologic ailments. 
Acharyas of Ayurveda has described many aspects of 
Mutravaha srotasa and described many diseases 
pertaining to Mutravaha srotasa (urinary system) like 
Mutraghata (urinary obstruction), Mutrakricchra 
(dysuria) and Mutrasmari (urinary calculus). Many 
herbs have been proven to be effectual as 
nephroprotective agents2 while, many more are claimed 
in the texts. Mulaka (Raphanus sativus Linn.) one of 
them which belongs to family Brasicassea and 
traditionally used in kidney disorders. The important 
Ayurvedic formulations of Mulaka, widely used in 
clinical practice for urinary disorders are Mulaka 
panchanga and Mulaka kshara mentioned in classics. 
Further, Ayurvedic Formulary of India mentioned 
Mulaka kshara indicated in mutrakrccha (dysuria), 
asmari (calculus), gulma (abdominal lump) and 
vatavikara (disorder due to vata dosa). The dose of 
Mulaka kshara is 1g per day3. 
Chemotherapy has been recognized to be 
efficacious in cancer treatment. Those agents usually 
demolish the physiological homoeostasis in various 
organs during treatment of cancer. Physiological side 
effects can occur that are induced in non tumor cells 
mostly by radical formation and oxidant injury4. 
Cisplatin is one of the most potent chemotherapeutic 
antitumor drugs which is inorganic platinum 
compound with a broad spectrum antineoplastic 
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activity against various types of tumors5. The chief 
dose limiting side effect of cisplatin is cumulative 
nephrotoxicity in man and in animals. Cisplatin is 
causing nephrotoxicity by recruiting oxidative stress, 
inflammation and cell death pathways6. 
Various medicinal plants that possessing 
nephroprotective activity may attenuate the kidney 
toxicity when co–administrated along with different 
nephrotoxic agents. In this background, it was thought 
worthwhile to evaluate the drugs which could be 
useful as adjuvant as nephroprotective agent. Further, 
rationale behind the concept on traditional uses of 
Mulaka (Raphanus sativus Linn.) has not well 
established through systematic pharmacological 
studies. Therefore, present study was planned to 
evaluate the Mulaka panchanga powder and Mulaka 
kshara for nephroprotective activity against cisplatin–
induced nephrotoxicity in wistar albino rats. 
 
Materials and Methods  
 
Drugs and chemicals 
Mulaka (Raphanus sativus Linn.) was cultivated at 
organic farm “Ram Vadi” of Anandabava Aashram, 
Jamnagar, Gujarat, India. The fresh matured samples 
of Mulaka was identified by Botanical Survey of 
India, Howrah with specimen No. VS 02 dated 30 
March 2015 and verified by the name of Raphnus 
sativus Linn. Family: Brassicaceae. Two different 
dosage forms, Mulaka panchanga powder and 
Mulaka kshara were taken for experimental study. 
Kshara was prepared with modified reference to 
Ayurvedic Formulary of India. Mulaka panchanga 
leaned with water, cut into small pieces and allowed 
to dry. After complete drying, the Mulaka panchanga 
was subjected for ash preparation. Obtained ash was 
used for Kshara jala preparation by addition of water 
in 6:1 ratio and kept the solution overnight. Next day, 
the supernant was collected by filtering through 
muslin cloth and collected solution was evaporated 
completely to obtain Mulaka kshara. All other 
chemicals used were of analytical grade. 
 
Animals 
Wistar albino rats of either sex weighing between 
200±20 g were procured from the Animal house 
attached to the Pharmacology laboratory, IPGT&RA, 
Gujarat Ayurved University. The animals were 
maintained as per standard husbandry conditions  
in terms of temperature (22±3ºC), relative humidity 
(50–60%) and 12 h light and dark cycle. The selected 
animals were kept under acclimatization for  
7 days before experiment started. Animals were  
fed with standard rat pellet feed and drinking water 
was given ad libitum. The experiments were carried 
out after approval of Institutional Animal Ethics 
Committee (IAEC/15/2013/43) in conformity with the 
guidelines of the CPCSEA, New Delhi. 
 
Dose calculation 
Dose of the drug was fixed by extrapolating the 
human dose to laboratory animals on the basis of 
body surface area ratio as per the table of Paget and 
Barnes (1964)7as given in Table 1. 
 
Experimental design 
Wistar albino rats of either sex weighing between 
200±20 g were divided into six groups, each consists 
of six rats (n=6). Group (I) kept as normal control 
group received distilled water (10 mL/kg, po), Group 
(II) was kept as cisplatin control (CG), received 
distilled water (10 mL/kg, po).Group (III) and (IV) 
treated with Mulaka kshara, at oral dose levels of 90 
and 180 mg/kg (MKL and MKH) respectively. Group 
(V) and (VI) treated with Mulaka panchanga powder, 
at oral dose levels of 450 and 900 mg/kg (MPL and 
MPH) respectively.  
The test drugs and distilled water to respective 
groups were administered for 10 days. On the 5th day 
of experiment, cisplatin was injected intraperitoneally 
at the dose of 5 mg/kg to all groups (II to VI) of 
animals except to normal control group (I). On 10th 
day, all rats were hydrated (2 mL/100 g) and kept 
under metabolic cages for urine collection for  
24 h. The animals were weighed again on 11th day, 
blood was collected from retro orbital plexus  
under light ether anesthesia for estimation of serum 
biochemical parameters. Thereafter, animals were 
sacrificed and important organs were dissected out, 
cleaned off and wet weight was noted down. Kidney 
sample was transferred to 10% buffered formalin 
solution and sent for histopathological study  
while, other kidney collected for tissue homogenate 
parameters.  
Serum biochemical parameters were carried out 
using fully automated biochemical random access 
analyzer (BS–200, Lilac Medicare Pvt. Ltd., 
Table 1 — Animal dose of test drugs 
Drugs Human dose 
(g/day) 
Animal dose 
(mg/kg) 
Mulak panchangapowder 5 g/day 450 mg/kg 
Mulak kshara 1 g/day 90 mg/kg 
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Mumbai). The parameters were blood sugar, serum 
cholesterol, triglycerides, HDL–cholesterol, SGPT, 
SGOT, blood urea, uric acid, total protein, calcium, 
albumin, globulin, total bilirubin, direct bilirubin, 
creatinine, and alkaline phosphatase. 
The kidneys were dissected out immediately, 
chilled and perfused with ice–cold saline. After 
washing with ice–cold saline, the kidneys were patted 
dry and weighed, and divided into fragments. One 
fragment was used to prepare homogenate (2.5% w/v) 
in normal saline. The homogenates were centrifuged 
at 4000 × g for 10 minutes at 4°C and the supernatants 
were used for the total protein8, lipid peroxidase9, 
catalase10, nitric oxide11, lactase dehydrogenase12, 
superoxide dismutase13 and alkaline phosphatase14. 
Second fragment homogenized (5% w/v) in 3% 
metaphosphoric acid solution for total glutathione15 
and glutathione peroxidase16. For histopathological 
study, kidney was carefully dissected, cleaned of 
extraneous tissue and was transferred to 10% buffered 
formalin solution for fixation for histopathological 
studies. 
 
Statistical analysis 
The data are expressed as mean±standard error of 
mean for six rats per experimental group. One way 
analysis of variance (ANOVA) was used to compare 
the mean values of quantitative variables among the 
groups followed by Dunnett’s multiple t-test and 
Students t-test for unpaired data as applicable to 
determine significant difference between groups at  
p<0.05. 
 
Result and Discussion 
Cisplatin (cis–diamminedichloroplatinum II,) is an 
inorganic complex formed by an atom of platinum 
surrounded by chloride and ammonia atoms in  
cis– position of a horizontal plane. It is a major  
anti– neoplastic drug for the treatment of various 
forms of cancers, with cisplatin therapy the major 
organs accumulating platinum are the kidneys,  
the liver and the spleen. In the kidney, cisplatin 
causing nephrotoxicity is there by recruiting oxidative  
stress, inflammation, and cell death pathways17. The 
exact mechanisms of cisplatin–induced nephrotoxicity 
are still not fully understood. However, lipid 
peroxidation and free radical generation in the tubular 
cells have been suggested to be responsible for the 
nephrotoxicity18. 
Cisplatin treatment resulted in significant reduction 
in body weight, significant increase in relative weight 
of kidney and liver in comparison to control group. 
Prior treatment with drugs resulted in protection 
against the cisplatin–induced deleterious effects on 
general health and relative weight of kidney and  
liver. Mulaka kshara at both dose levels produced 
significant decrease while, Mulaka panchanga 
powder produced non–significant decrease in relative 
weight of kidney in comparison to cisplatin control 
group (Table 2). Cisplatin–induced weight loss, 
already reported by previous authors, may be due  
to gastrointestinal toxicity or by lessened ingestion  
of food19. 
The plasma concentrations of urea and creatinine 
determine renal function and are thus, biomarkers for 
kidney disease. In present study, the increased levels 
of blood urea, uric acid and serum creatinine and 
urine creatinine due to administration of cisplatin in 
rats signify the severe kidney damage in rats20. 
Mulaka kshara at both the dose levels produced 
significant decrease while, Mulaka panchanga 
produced non–significant decrease in serum creatinine 
Table 2 — Effect of test drugs on the body weight and relative weight of organs in cisplatin–induced kidney damage in rats 
Parameters NC CC MKL MKH MPL MPH 
Initial body  
weight (g) 
210.00±5.34 197.00±5.79 204.00±4.03 204.66±6.86 197.33±7.58 211.00±4.05 
Final Body  
weight (g) 
207.00±5.90 179.33±7.11@# 173.33±6.48@ 170.00±7.60@ 177.33±9.08** 187.66±7.80 
Heart (g/100g  
body weight) 
0.308±0.007 0.296±0.011 0.354±0.016* 0.334±0.013 0.322±0.018 0.276±0.019 
Liver (g/100g  
body weight) 
2.873±0.113 3.305±0.105## 3.236±0.102 3.163±0.237 2.888±0.126* 3.121±0.052 
Kidney (g/100g  
body weight) 
0.694±0.009 0.897±0.023### 0.792±0.035* 0.805±0.031* 0.855±0.055 0.875±0.031 
 01.42↓ 09.13↓ 15.03↓ 16.93↓ 10.13↓ 11.05↓ 
Data: Mean±SEM; *p<0.05, **p<0.01, *p<0.001 when compared with initial body weight (Paired‘t’ test); 
#p<0.02,##p<0.05, ###p<0.001when compared with normal control group (Unpaired t-test). 
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and blood urea level in comparison to cisplatin 
control group. However, drugs did not affect the 
serum uric acid and urine creatinine level in 
comparison to cisplatin control group (Table 3).  
Cisplatin administration in rats non–significantly 
decreases the blood glucose level and significantly 
increased the serum cholesterol and triglyceride level 
in comparison with control group. The results suggest 
the deteriorating role of cisplatin on carbohydrates 
and lipid metabolism due to its liver toxicity in rats. 
Mulaka panchanga powder at both dose levels 
significantly revert the blood glucose level while, 
triglyceride level was significantly decreases by 
Mulaka kshara in doses dependent manner. HDL–
cholesterol level was significantly increase by  
Mulaka kshara at both dose levels and powder at 
higher dose level. Previous report also suggests that, 
Raphanus sativus can decrease the plasma cholesterol, 
triglyceride and phospholipids in normal rats. 
Consequently in the present study, the significant 
decrease in albumin may be evidence on cisplatin–
induced nephrotoxicity. The significant alleviation in 
albumin level due to prior administration of test  
drugs also provides the evidence of protective role  
of Mulaka to alleviate nephrotoxicity (Table 3).  
Oxidative stress is one of the key mechanisms by 
which cisplatin perpetuate renal tissue injury21. 
Therefore, present study investigated the various 
endogenous markers of oxidative stress and anti–
oxidant parameters in kidney tissue homogenate. 
Treatment of rats with cisplatin results in a significant 
increase in the activity of calcium–independent nitric 
oxide synthase in kidney and liver leading to 
enhanced nitric oxide formation22. Stress to the 
epithelial cells caused an increase in immune 
detectable inducible NO synthase (iNOS). Nitric 
oxide is known to react with the superoxide radical, 
forming peroxynitrite, an even more potent oxidizing 
agent. Peroxynitrite can react directly with sulfhydryl 
residues in the cell membrane leading to lipid 
peroxidation or with DNA resulting in cytotoxicity23. 
Administration of cisplatin in rats produced  
non–significant decrease in nitric oxide level in 
comparison to normal control group which may be 
due to decrease in cNOS. Test drugs at both dose 
levels significantly revert the nitric oxide level in 
compared to CC group. 
Cisplatin–induced cardiotoxicity could be a 
secondary event following cisplatin–induced lipid 
peroxidation of cardiac membranes with the 
consequent increase in the leakage of LDH from 
cardiac myocytes24. Serum alkaline phosphatase and 
transaminases are cytoplasmic in location and are 
released in to circulation after cellular damage. Serum 
alkaline phosphatase increased while, decrease in 
kidney homogenate suggests the damage to kidney 
tissue. Administration of cisplatin in rats produced 
non–significant increase in LDH. All groups of test 
drugs treated reversed both the parameters but, 
significant result observed for LDH by MKH, MPL, 
Table 3 — Effect of test drugs on serum biochemical parameters in cisplatin–induced kidney damage in rats 
Parameters NC CC MKL MKH MPL MPH 
Glucose (mg/dl) 63.16±4.078 52.16±1.66# 55.83±4.04 48.83±4.34 66.00±4.27* 66.83±3.33@ 
Cholesterol (mg/dl) 42.16±1.53 45.50±2.06 56.33±6.32 66.00±3.74@ 49.66±2.29 56.33±3.40* 
Triglycerides (mg/dl) 53.80±13.39 105.8±15.75# 63.40±3.72* 53.40±3.75** 68.20±8.11 75.00±8.69 
HDL–Chol. (mg/dl) 31.33±1.20 32.50±1.52 39.50±1.94** 42.00±6.95@ 34.16±2.86 39.66±0.91@ 
SGPT (IU/dl) 54.66±3.49 52.16±11.16 57.16±9.76 56.66±6.10 67.83±6.26 63.16±3.76 
SGOT (IU/dl) 156.83±8.15 117.33±30.97 171.50±18.56 158.00±16.88 172.66±12.18 174.83±10.39 
ALP (IU/dl) 117.33±14.76 168.00±28.13 107.16±35.79 65.83±6.48@ 147.50±38.02 96.50±8.717 
Urea (mg/dl) 38.83±6.18 61.66±19.43 50.80±10.80 38.40±4.36 68.67±12.17 49.67±11.46 
Creatinine (mg/dl) 0.91±0.038 2.84±0.225# 1.28±0.358@ 1.29±0.139@@ 2.00±0.318 2.44±0.559 
Total protein (g/dl) 6.40±0.191 6.35±0.411 6.90±0.349 6.85±0.198 6.58±0.168 6.91 ±0.373 
Albumin (g/dl) 3.93±0.08 3.90±0.16 3.96±0.14 3.95±0.08 3.96±0.13 3.96±0.11 
Globulin (g/dl) 2.46±0.143 2.45±0.305 2.93±0.220 2.90±0.183 2.61±0.122 2.95±0.382 
T. Bilirubin (mg/dl) 0.683±0.087 0.767±0.136 0.800±0.129 0.567±0.084 0.650±0.131 0.733±0.095 
D. Bilirubin (mg/dl) 0.200±0.026 0.350±0.152 0.233±0.042 0.167±0.021 0.183±0.031 0.233±0.042 
Uric acid (mg/dl) 1.03±0.042 1.20±0.234 1.45±0.171 1.30±0.139 1.21±0.149 1.03±0.152 
Calcium (mg/dl) 10.41±0.172 10.06±0.105 9.58±0.210 10.0±0.191 9.73±0.242 9.98±0.306 
Data: Mean±SEM; #p<0.05 when compared with normal control group; *p<0.05, **p<0.02, *p<0.01,**p<0.001 when compared with CC 
group (Unpaired t-test). 
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MPH when compared to cisplatin control group 
suggesting that drug may have potential protective 
effect against cisplatin–induced cardiac and kidney 
damage(Table 4). 
Catalase is an enzymatic antioxidant and helps in 
neutralizing the toxic effect of H2O2. Hydrogen 
peroxide is not reactive enough to cause a chain of 
lipid peroxidation reactions, but its combination with 
super oxide radical produces hydroxyl radical that is 
highly reactive and thus initiates lipid oxidation 
reactions25. Mulaka kshara and panchanga increases 
the catalase, but significant result observed in MPH 
group in comparison to cisplatin control group. 
Treatment with Mulaka kshara and Panchanga 
significantly ameliorated renal tissue injury by 
significantly decreasing lipid peroxidation. Mulaka 
formulations inhibit lipid peroxidation and provide 
protection by strengthening the antioxidants like 
glutathione and catalase level in kidney26. 
GSH protects the biomolecules from oxidative 
tissue damage by scavenging ROS27. Decreased GSH 
levels in the renal tissues further perpetuates 
cisplatin–induced renal damage. The depletion of 
GSH seems to be a prime factor that permits lipid 
peroxidation28.Glutathione is one of the essential 
compounds for regulation of variety of cell functions. 
It has a direct antioxidant function by reacting with 
superoxide radicals, peroxy radicals and singlet 
oxygen followed by the formation of oxidized 
glutathione (GS–SG) and other disulfides. Glutathione 
S–transferase (GST) and Glutathione peroxidase 
(GSH–Px) are GSH–dependent antioxidant enzymes29. 
Many of the earlier experimental studies demonstrated 
the depletion of renal GSH concentration and 
antioxidant activities in cisplatin–induced renal 
damage30,31. Therefore, administration of exogenous 
GSH or its esters effectively protected cisplatin–
mediated renal toxicity32. In present study, 
administration of cisplatin in rats produced significant 
decrease in the total glutathione and non–significantly 
decreases in glutathione peroxidase suggest the 
deterioration  
of defense mechanism. Administration of Mulaka 
panchanga powder produced significant increase in 
glutathione while, Mulaka kshara produced non–
significant increase in glutathione and significant 
increase in GPx content in kidney homogenate in 
comparison to cisplatin control group (Table 4). 
Cisplatin–induced renal damage is associated with 
increased renal vascular resistance and histologic 
damage to proximal tubular cells33. In this present 
study, histopathological examination cisplatin 
showed, fatty degenerative and cell infiltration  
due to inflammation, loss of cytoarchitecture  
indicate nephrotoxicity–induced in rats by cisplatin in 
comparison to normal control group. Treatment with 
Mulaka panchanga attenuates changes like, mild fatty 
and edematous changes. At higher dose, almost 
Table 4 — Effect of test drugs on tissue biochemical parameters in cisplatin–induced kidney damage in rats 
Parameters NC CC MKL MKH MPL MPH 
Total Protein  
(mg/g tissue) 
49.66±1.58 45.82±1.48 46.33±1.12 45.44±1.24 50.75±4.71 45.44±2.09 
Total Glutathione  
(n mol/gm) 
1158.33±93.51 933.06±32.23# 1037.35±45.06 973.38±37.84 1201.44±69.37** 1172.23±77.78* 
GPx (nmole of GSH 
utilized/min) 
1.086±0.071 0.971±0.033 1.996±0.278** 2.039±0.224@ 2.431±0.395** 2.310±0.282@ 
Catalase  
(Unit/mg protein) 
3.70±0.181 3.77±0.23 4.09±0.190 4.44±0.204 4.25±0.330 4.61±0.210** 
LPO (n moles of MDA 
formed /g tissue) 
21.76±2.56 43.54±8.55# 20.32±4.52* 13.96±1.52** 24.15±7.02 15.44±2.01* 
Nitric oxide  
(μ mole/g tissue) 
3.73±0.24 3.33±0.830 4.81±0.354 4.17±0.448 3.75±0.603 3.52±0.290 
LDH (μ mole  
pyruvate liberated/ gm 
tissue/min.) 
34.69±0.94 37.84±1.44 30.96±4.04 29.45±2.79* 18.48±0.91@ 22.54±3.37** 
ALP (µmole of 
phenol/mg protein 
/min.) 
2.09±0.157 1.08±0.142## 1.37±0.121 1.75±0.182* 1.35±0.173 1.63±0.160* 
Data: Mean±SEM; #p<0.05 ,##p<0.01 when compared with normal control group; *p<0.05, **p<0.01, *p<0.01when compared with CC 
group (Unpaired t-test). 
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normal cytoarchitecture in Mulaka panchanga  
powder administered group. However, in kshara 
treated group mild to moderate fatty degenerative  
and edematous changes and nearly normal 
cytoarchitecture showed in comparison to cisplatin 
control group (Fig. 1 & 2). The findings of serum 
biochemical and tissue parameters are well supported 
by histopathological study in which, the kidney  
of treated rats clearly indicate Mulaka panchanga  
and kshara at both doses level have protective  
effects kidney cytoarchitecture from damaged by 
cisplatin. 
 
 
Fig. 1 — Photomicrographs of representative sections of Kidney taken at x 400 magnification. (a) Normal cytoarchitecture (Normal 
Control group) (b) Fatty degenerative and cell infiltration due to inflammation (Cisplatin control group) (c) Sever fatty degenerative and 
inflammatory changes, loss of cytoarchitecture (Cisplatin Control group) (d) Sever fatty degenerative and inflammatory changes, loss of 
cytoarchitecture (Cisplatin Control group) 
 
 
 
Fig. 2 — Photomicrographs of sections of Kidney taken at x 400 magnification. (a) Moderate fatty degenerative and inflammatory 
changes (MKL group) (b) Almost normal cytoarchitecture (MKH group) (c) Mild fatty changes, inflammatory cells and oedema in 
tubules (MPL) (d) Mild fatty and oedematous changes in tubules(MPH) 
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Conclusion 
From the present study it is concluded that,  
Mulaka panchanga and Mulaka kshara both having 
nephroprotective and antioxidant properties in dose 
dependent manner in cisplatin– induced nephrotoxicity 
in rats. Flavonoids present in all parts of Mulaka 
(Raphanus sativus Linn.) in varied quantity and are 
known to modulate the activities with various 
biomolecules. Carotenoids, kaempferol and quercetin 
are well known free radical scavengers present in 
Mulaka. Hence, the possible mechanism of Mulaka 
panchanga powder exerts nephroprotection could be 
attributed to its free radical scavenging property and 
its diuretic activity. 
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